The FDA Just Changed the Peptide Conversation: Here’s What Happened
Something significant just happened in the world of peptides.
On July 23–24, the FDA’s Pharmacy Compounding Advisory Committee considered seven widely discussed peptides and voted in favor of six: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, while rejecting DSIP (emideltide).
But these votes are widely misunderstood.
In this Energy Code Deep Dive, Dr. Mike Belkowski breaks down what the committee actually voted on, why a YES vote is not FDA drug approval, and the debate that divided the committee: should promising but under-studied peptides remain largely in the gray market, or could…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.